The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data

References

• SidburyR, KodamaS. Atopic dermatitis guidelines: diagnosis, systemic therapy, and adjunctive care. Clin Dermatol. 2018;36:648–652. doi:10.1016/j.clindermatol.2018.05.00830217277
   PubMed Web of Science ®Google Scholar
• TorresT, FerreiraEO, GonçaloM, Mendes-BastosP, SeloresM, FilipeP. Update on atopic dermatitis. Acta Med Port. 2019;32:606–613. doi:10.20344/amp.1196331493365
   PubMed Web of Science ®Google Scholar
• NapolitanoM, RuggieroA, FontanellaG, FabbrociniG, PatrunoC. New emergent therapies for atopic dermatitis: a review of safety profile with respect to female fertility, pregnancy, and breastfeeding. Dermatol Ther. 2020;e14475.33128337
   PubMed Web of Science ®Google Scholar
• SzalusK, TrzeciakM, NowickiRJ. JAK-STAT inhibitors in atopic dermatitis from pathogenesis to clinical trials results. Microorganisms. 2020;8:E1743. doi:10.3390/microorganisms811174333172122
   PubMed Web of Science ®Google Scholar
• HeH, Guttman-YasskyE. JAK inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20:181–192. doi:10.1007/s40257-018-0413-230536048
   PubMed Web of Science ®Google Scholar
• CzarnowickiT, KruegerJG, Guttman-YasskyE. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017;139:1723–1734. doi:10.1016/j.jaci.2017.04.00428583445
   PubMed Web of Science ®Google Scholar
• CzarnowickiT, GonzalezJ, ShemerA, et al. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. J Allergy Clin Immunol. 2015;136:104–115. doi:10.1016/j.jaci.2015.01.02025748064
   PubMed Web of Science ®Google Scholar
• WerfelT, AllamJ-P, BiedermannT, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138:336–349. doi:10.1016/j.jaci.2016.06.01027497276
   PubMed Web of Science ®Google Scholar
• Guttman-YasskyE, WaldmanA, AhluwaliaJ, OngPY, EichenfieldLF. Atopic dermatitis: pathogenesis. Semin Cutan Med Surg. 2017;36:100–103. doi:10.12788/j.sder.2017.03628895955
   PubMed Web of Science ®Google Scholar
• ChuCY. Treatments for childhood atopic dermatitis: an update on emerging therapies. Clin Rev Allergy Immunol. 2020. doi:10.1007/s12016-020-08799-1
   Web of Science ®Google Scholar
• SalimiM, BarlowJL, SaundersSP, et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med. 2013;210:2939–2950. doi:10.1084/jem.2013035124323357
   PubMed Web of Science ®Google Scholar
• BrunnerPM, Guttman-YasskyE, LeungDY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139:S65–S76. doi:10.1016/j.jaci.2017.01.01128390479
   PubMed Web of Science ®Google Scholar
• Gutowska-OwsiakD, SchauppAL, SalimiM, et al. IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol. 2012;21:104–110. doi:10.1111/j.1600-0625.2011.01412.x22229441
   PubMed Web of Science ®Google Scholar
• CotterDG, SchairerD, EichenfieldL. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol. 2018;78:S53–S62. doi:10.1016/j.jaad.2017.12.01929248518
   PubMed Web of Science ®Google Scholar
• VillarinoAV, KannoY, O’SheaJJ. Mechanisms and consequences of Jak–STAT signaling in the immune system. Nat Immunol. 2017;18:374–384. doi:10.1038/ni.369128323260
   PubMed Web of Science ®Google Scholar
• FerreiraS, Guttman-YasskyE, TorresT. Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib. Am J Clin Dermatol. 2020;21:783–798. doi:10.1007/s40257-020-00548-632776305
   PubMed Web of Science ®Google Scholar
• CrowleyEL, NezamololamaN, PappK, GooderhamMJ. Abrocitinib for the treatment of atopic dermatitis. Expert Rev Clin Immunol. 2020;16:955–962. doi:10.1080/1744666X.2021.182806832969750
   PubMed Web of Science ®Google Scholar
• BaoL, ZhangH, ChanLS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013;2:e24137. doi:10.4161/jkst.2413724069552
   PubMedGoogle Scholar
• NapolitanoM, MarascaC, FabbrociniG, PatrunoC. Adult atopic dermatitis: new and emerging therapies. Expert Rev Clin Pharmacol. 2018;11:867–878. doi:10.1080/17512433.2018.150773430073901
   PubMed Web of Science ®Google Scholar
• RodriguesMA, TorresT. JAK/STAT inhibitors for the treatment of atopic dermatitis. J Dermatolog Treat. 2020;31:33–40. doi:10.1080/09546634.2019.157754930703333
   PubMed Web of Science ®Google Scholar
• NapolitanoM, FabbrociniG, CinelliE, StingeniL, PatrunoC. Profile of baricitinib and its potential in the treatment of moderate to severe atopic dermatitis: a short review on the emerging clinical evidence. J Asthma Allergy. 2020;13:89–94. doi:10.2147/JAA.S20638732099414
   PubMed Web of Science ®Google Scholar
• New oral treatment for moderate to severe atopic dermatitis. Available from: https://www.ema.europa.eu/en/news/new-oral-treatment-moderate-severe-atopic-dermatitis. Accessed 118, 2021.
   Google Scholar
• GooderhamMJ, FormanSB, BissonnetteR, et al. Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155:1371–1379. doi:10.1001/jamadermatol.2019.285531577341
   PubMed Web of Science ®Google Scholar
• PeevaE, HodgeMR, KierasE, et al. Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: a Phase 1, randomized, placebo-controlled, dose-escalation study. Br J Clin Pharmacol. 2018;84:1776–1788. doi:10.1111/bcp.1361229672897
   PubMed Web of Science ®Google Scholar
• SimpsonEL, SinclairR, FormanS, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, Phase 3 trial. Lancet. 2020;396:255–266. doi:10.1016/S0140-6736(20)30732-732711801
   PubMed Web of Science ®Google Scholar
• SilverbergJI, SimpsonEL, ThyssenJP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156:863–873. doi:10.1001/jamadermatol.2020.140632492087
   PubMed Web of Science ®Google Scholar
• Study evaluating efficacy and safety of PF-04965842 and dupilumab in adult subjects with moderate to severe atopic dermatitis on background topical therapy (JADE compare). Available from: https://www.clinicaltrials.gov/ct2/show/NCT03720470?term=NCT03720470&draw=2&rank=1. Accessed 118, 2021.
   Google Scholar
• Study to investigate efficacy and safety of PF-04965842 in subjects aged 12 years and over with moderate to severe atopic dermatitis with the option of rescue treatment in flaring subjects. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03627767?term=abrocitinib&cond=Atopic+Dermatitis&draw=2&rank=5. Accessed 118, 2021.
   Google Scholar
• Study to evaluate efficacy and safety of PF-04965842 with or without topical medications in subjects aged 12 years and older with moderate to severe atopic dermatitis (JADE EXTEND). Available from: https://www.clinicaltrials.gov/ct2/show/NCT03422822?term=abrocitinib&cond=Atopic+Dermatitis&draw=2&rank=3. Accessed 118, 2021.
   Google Scholar
• Study of abrocitinib compared with dupilumab in adults with moderate to severe atopic dermatitis on background topical therapy. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04345367?term=abrocitinib&cond=Atopic+Dermatitis&draw=2&rank=2. Accessed 118, 2021.
   Google Scholar
• Abrocitinib expanded access protocol in adolescents and adults with moderate to severe atopic dermatitis. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04564755?term=abrocitinib&cond=Atopic+Dermatitis&draw=2&rank=1. Accessed 118, 2021.
   Google Scholar
• Study evaluating the mechanism of action of PF-04965842 monotherapy for moderate-to-severe atopic dermatitis (JADE MOA). Available from: https://www.clinicaltrials.gov/ct2/show/NCT03915496?term=abrocitinib&cond=Atopic+Dermatitis&draw=2&rank=4. Accessed 118, 2021.
   Google Scholar